Skip to content
← Full study record

NCT05883449 · MORE INFO

Limitations, agreements, and source contact

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL · Source last updated 2025-08-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The sponsor has the right to review communications for 90 days prior to public release (whereby the sponsor may ask to consider modifications to ensure necessary protection of sponsor's IP). Any publication shall be not made before the first multi-centre publication if the study is a part of a multi-centred clinical trial. Also, if a publication concerns the analyses of data from a multi-centred clinical trial, the communication shall make reference to the relevant multi-centre publication
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The decision to terminate this study was based solely on the financial situation of the company and was not related to the safety or efficacy. Given this limitation, the results of the time to event endpoints are premature.
point Of Contact
email
trials@affimed.com
organization
Affimed GmbH
phone
+49 621 560030
title
Clinical Operations
Complete source fields
certain Agreement
other Details
The sponsor has the right to review communications for 90 days prior to public release (whereby the sponsor may ask to consider modifications to ensure necessary protection of sponsor's IP). Any publication shall be not made before the first multi-centre publication if the study is a part of a multi-centred clinical trial. Also, if a publication concerns the analyses of data from a multi-centred clinical trial, the communication shall make reference to the relevant multi-centre publication
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The decision to terminate this study was based solely on the financial situation of the company and was not related to the safety or efficacy. Given this limitation, the results of the time to event endpoints are premature.
point Of Contact
email
trials@affimed.com
organization
Affimed GmbH
phone
+49 621 560030
title
Clinical Operations

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice